Login to Your Account

Regulatory NEWS

NEW DELHI – India is considering making its voluntary Uniform Code of Pharmaceuticals Marketing Practices mandatory to curb unfair marketing practices by pharma companies, including providing incentives for doctors to prescribe their products.

Although the FDA approved its fourth biosimilar Friday – Amgen Inc.'s Amjevita, which references Abbvie Inc.'s blockbuster Humira – the U.S. is not much closer to having a truly competitive biosimilars market, as only one biosimilar has actually launched.

WASHINGTON – For FDA commissioner Robert Califf, combination products are "definitely on my mind right now," but he noted that various centers at the agency will have to rewire their thinking in order to accommodate what is expected to be a growing volume of combination product applications.

More Regulatory Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: